The radionuclide imaging and therapy for metastatic prostate cancer
10.3760/cma.j.cn112330-20210907-00474
- VernacularTitle:转移性前列腺癌的核素显像检查与核素治疗进展
- Author:
Xuexin HE
1
;
Jinyun ZHOU
;
Haoran LI
;
Chentao JIN
;
Mei TIAN
Author Information
1. 浙江大学医学院附属第二医院肿瘤内科，杭州 310009
- Keywords:
Prostatic neoplasms;
Metastatic prostate cancer;
Prostate-specific membrane antigen;
Radioligand therapy;
Radionuclide imaging;
Radionuclide therapy
- From:
Chinese Journal of Urology
2021;42(10):792-796
- CountryChina
- Language:Chinese
-
Abstract:
Metastatic prostate cancer is one of the most malignancies and do harm to the health and life expectancy of men. The popularization and application of 68Gallium or 18Fluorine labeled prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) benefit for the excellent diagnostic efficacy, unique value in the diagnosis of metastatic prostate cancer, clinical decision-making guidance, efficacy in monitoring and prognosis evaluation. 223Radium and 177Lu-PSMA radioligand therapy (RLT) could effectively alleviate bone pain, and prolong the overall survival time (OS) as wellas progression-free survival time (PFS) with good safety. In addition, survival of patients with metastatic prostate cancer is expected to be further improved with the advance in the combination therapies with PSMA RLT, androgen-deprivation therapy (ADT), chemotherapy, targeted therapy and immunotherapy.
